Amylin deposition in the brain: A second amyloid in Alzheimer disease?
Version of Record online: 12 JUL 2013
© 2013 American Neurological Association
Annals of Neurology
Volume 74, Issue 4, pages 517–526, October 2013
How to Cite
Jackson, K., Barisone, G. A., Diaz, E., Jin, L.-w., DeCarli, C. and Despa, F. (2013), Amylin deposition in the brain: A second amyloid in Alzheimer disease?. Ann Neurol., 74: 517–526. doi: 10.1002/ana.23956
- Issue online: 26 NOV 2013
- Version of Record online: 12 JUL 2013
- Accepted manuscript online: 22 JUN 2013 04:27AM EST
- Manuscript Accepted: 24 MAY 2013
- Manuscript Revised: 10 MAY 2013
- Manuscript Received: 15 OCT 2012
Additional supporting information can be found in the online version of this article.
Fig S1 – Immunoreactivity of amylin antibody in solutions of recombinant amylin vs Aβ.
Fig S2 – Specificity of amylin antibody on western blot.
Fig S3 – Electrophoretic pattern of amylin analyzed with two different antibodies (top). Both antibodies effectively stain amylin deposits (bottom).
Fig S4 – Electrophoretic patterns of amylin and proamylin in brain protein homogenates.
Fig S5 - Typical distribution of amylin plaques in brain parenchyma of diabetic patients without vascular dementia (T2D-D).
Fig S6 – Typical distribution of amylin plaques in brain parenchyma of AD patients without T2D (AD group).
Fig S7 – Typical distribution of amylin plaques in brain parenchyma of humans in the control group.
Fig S8 – Serial staining with anti-amylin antibody, anti-Aβ antibody, and Congo red of a brain sample from a T2D patient with vascular dementia. The lower panel at the right shows the Congo red stain of the same tissue area under a polarized light microscope. Amylin deposits exhibit apple-green birefringence demonstrating that amylin forms amyloid-like structure in the brain.
Table 1 - Etiology of cerebral and vascular disorders, age, gender, and diabetes status of T2D cases with cerebrovascular disease and dementia (T2D-D group).
Table 2 - Etiology of cerebral and vascular disorders, age, and gender of AD cases without overt T2D (AD group).
Table 3 – Gender and age of cases in the control group.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.